Guest guest Posted September 3, 2006 Report Share Posted September 3, 2006 OS ANGELES, Aug 24 (Reuters) - Dendreon Corp. (DNDN.O: Quote, Profile, Research) said on Thursday that it has filed the safety and efficacy portions of a U.S. Food and Drug Administration application for an experimental prostate cancer drug and expects to submit the chemistry and manufacturing segment by the end of the year. " We will apply for a priority review, which means a 6-month clock for the FDA. We could get approval in mid-2007, " said Chief Executive Gold. Seattle-based Dendreon is seeking clearance to market Provenge, which is designed to work by stimulating a patient's immune system against cancer cells, as a treatment for men with late-stage prostate cancer. If approved, the drug would be the first therapeutic cancer vaccine. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.